Leonardo Roever: CHR as a Composite Biomarker for Stroke Risk Stratification
Leonardo Roever, CEO of Brazilian Evidence-Based Health Network, shared on LinkedIn about a recent article by Wei Huang et al, published in Lipids in Health and Disease:
”Association of C-reactive protein/HDL cholesterol ratio with stroke in Chinese adults with different glycemic levels
Stroke is one of the major public health problems in China, highlighting the need for accessible biomarkers to aid in risk stratification.
The C-reactive protein/HDL cholesterol (CHR) ratio, which integrates inflammatory and lipid pathways, has emerged as a new composite biomarker.
Higher CHR levels were associated with an increased risk of stroke in Chinese adults, with heterogeneity between different glycemic levels, showing stronger and nonlinear (J-shaped) associations in individuals with normal blood glucose than in individuals with diabetes.
CHR has demonstrated limited discriminatory ability for stroke, suggesting that its usefulness may lie in risk stratification rather than isolated prediction.
Follow me for more content on evidence, management, and innovation in health
Enroll now in the courses offered by the Brazilian Evidence-Based Health Network and take your research and scientific knowledge to the next level.”
Title: Association of C-reactive protein/high-density lipoprotein cholesterol ratio with stroke in Chinese adults across different glycemic status
Authors: Wei Huang, Jun Gu, Xueli Sun, Zhimei Shen, Qin Yin, Xu Wang
Read the Full Article on BMC/Lipids in Health and Disease

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series